OLMA — Olema Oncology, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1750284 ·
Last close
$7.22
Market Cap
$632.52M
52W High
$36.26
52W Low
$6.24
ADV30
1,426,785
Next earnings
2026-11-10
Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as Olema Pharmaceuticals, Inc. and changed its name to Olema Oncology, Inc. in November 2026. Olema Oncology, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -77,525,000 -73,599,000 441,070,000 47,522,000 72,233,000
Jun 2026 0 — -67,179,000 -63,200,000 486,578,000 48,599,000 56,014,000
Mar 2026 0 — -57,986,000 -53,089,000 530,645,000 52,547,000 50,167,000
Dec 2025 0 — -50,084,000 -46,061,000 533,430,000 48,301,000 54,871,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-177,322,000
Investing CF
$-71,213,000
Financing CF
$260,797,000
CapEx
$-900,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.35
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-787,445,000
Inventory
—
Receivables
$3,374,000
ST Investments
$366,249,000
EBIT TTM
$-252,774,000
Pretax Income TTM
$-235,949,000
Interest Exp TTM
—
Analysts
10

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -178,698,000 -162,451,000 533,430,000 54,871,000 478,559,000 -146,716,000
Dec 2024 0 -142,258,000 -129,474,000 450,979,000 42,015,000 408,964,000 -104,351,000
Dec 2023 0 -104,961,000 -96,655,000 276,945,000 23,050,000 253,895,000 -83,727,000
Dec 2022 0 -106,988,000 -104,787,000 215,645,000 18,099,000 197,546,000 -82,065,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$16,941,000
NetIncome TTM
$-204,567,000
OpCashFlow TTM
—
Assets (Latest)
$486,578,000
Forward EPS
$-2.90

Max Pain — expiry 2026-12-18

max pain strike: $10.00 · spot: $7.06 · call oi: 4,410 · put oi: 1,368
Expected Move to 2026-12-18: ±$2.15 (30.45%) — implied range $4.91 – $9.21 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DSGN Design Therapeutics, Inc. $630.12M $9.84 —
ALMS ALUMIS INC. $628.33M $4.84 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —
GERN GERON CORP $644.24M $1.00 —

News headlines (Yahoo Finance, 1h cache)

Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
2026-11-18 07:30 · Yahoo
Olema Oncology to Participate in Upcoming Investor Conferences
2026-11-16 21:30 · Yahoo
Olema Oncology Announces Corporate Name Change
2026-11-12 14:00 · Yahoo
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
2026-11-10 12:00 · Yahoo
Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
2026-11-04 21:01 · Yahoo
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 21:30 · Yahoo
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
2026-09-14 12:10 · Yahoo
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
2026-08-10 20:01 · Yahoo
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?
2026-06-30 12:07 · Yahoo
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
2026-10-05 14:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.